Published
GLP-1 Receptor Biology Explained — From Exendin to Retatrutide
The evolution of the incretin class — GLP-1 alone, dual GIP/GLP-1 (Tirzepatide), to triple GIP/GLP-1/glucagon (Retatrutide). Mechanism and the rationale for adding receptors.
The incretin peptide class has undergone the fastest pharmacological evolution of any drug category in recent medical history. From the discovery of glucagon-like peptide-1 as a physiological gut hormone in the 1980s to the triple-agonist Retatrutide entering Phase III trials in the 2020s, the trajectory compresses thirty years of receptor biology into a clinical narrative that now directly touches the mainstream research-peptide conversation. Understanding the receptor biology behind this class explains why successive generations of compounds produce progressively larger metabolic effects.
The physiological origin of GLP-1
Glucagon-like peptide-1 is a 30-amino-acid peptide produced by L-cells in the distal small intestine and colon in response to nutrient ingestion. Its primary physiological function is the augmentation of glucose-dependent insulin secretion from pancreatic β-cells — the so-called "incretin effect," which accounts for approximately 50–70% of postprandial insulin release in healthy subjects [PMID:15959528].
The foundational endocrinology was established by Daniel Drucker's laboratory at the University of Toronto from the late 1980s through the 1990s. Drucker's group characterised GLP-1 receptor (GLP-1R) expression on pancreatic β-cells, demonstrated the glucose-dependence of the insulin-secretory response (critically, GLP-1 does not stimulate insulin secretion in the absence of glucose — a property that limits hypoglycaemia risk), and identified the rapid plasma inactivation of native GLP-1 by the enzyme dipeptidyl peptidase-IV (DPP-IV) [PMID:9843528].
GLP-1R: the primary receptor
The GLP-1 receptor is a class B G protein-coupled receptor (GPCR) that couples primarily to Gs, activating adenylyl cyclase and elevating intracellular cAMP. In pancreatic β-cells this drives insulin exocytosis in a glucose-dependent manner. Outside the pancreas, GLP-1R is expressed on:
- Vagal afferent neurones projecting to the nucleus tractus solitarius — mediating satiety signalling and reduced food intake
- Hypothalamic arcuate nucleus neurones, specifically on AgRP/NPY neurones (inhibition reduces appetite) and POMC neurones (activation increases satiety)
- Gastric smooth muscle — mediating delayed gastric emptying, which slows glucose absorption and prolongs satiety
- Cardiac myocytes — with a less well characterised cardioprotective function [PMID:16414296]
The net physiological result of GLP-1R agonism is: reduced appetite, reduced caloric intake, slower gastric emptying, and glucose-dependent insulin secretion. This is the mechanistic basis of the GLP-1 agonist class from exenatide through semaglutide.
The DPP-IV problem and pharmaceutical engineering
Native GLP-1 has a plasma half-life of 1–2 minutes due to DPP-IV cleavage at the Ala-Glu N-terminal bond. Developing a clinically useful GLP-1 agonist therefore required either DPP-IV resistance or formulation strategies to extend exposure.
The first solution was exendin-4, a naturally occurring 39-amino-acid peptide from the Gila monster (Heloderma suspectum) venom that is intrinsically DPP-IV resistant. Synthetic exendin-4 (exenatide, Byetta) received FDA approval in 2005 — the first GLP-1 receptor agonist in clinical practice, with a half-life of approximately 2.4 hours [PMID:17638583].
The second approach — fatty-acid acylation to extend albumin binding and delay renal clearance — produced liraglutide (Victoza, 2010; half-life 13 hours) and ultimately semaglutide (Ozempic, Wegovy; half-life ~168 hours, enabling once-weekly dosing via a C18 diacid linker to albumin). Semaglutide's pharmacokinetic engineering — extended albumin binding, prodrug-like release — represents the pinnacle of single-receptor GLP-1 agonism, producing approximately 15% mean body weight reduction in the STEP-1 trial [PMID:34170647].
GIP receptor: the controversial second agonist
Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone, produced by K-cells in the proximal small intestine. GIP receptor (GIPR) is expressed on pancreatic β-cells (augmenting insulin secretion), adipocytes, bone, and brain. The rationale for adding GIPR agonism to GLP-1R agonism was initially contentious.
GIP was historically associated with pro-obesity effects — GIPR knockout mice are protected from diet-induced obesity — and early research suggested GIPR agonism might oppose GLP-1R agonism on appetite. The resolution of this apparent paradox emerged from biased agonism research: at supraphysiological concentrations achieved by pharmaceutical agonists, GIPR activation on adipocytes enhances fatty acid uptake, but the dominant net effect in combination with GLP-1R agonism appears to be additive weight reduction through complementary central mechanisms [PMID:33197385].
Tirzepatide (Mounjaro; Zepbound), the dual GIP/GLP-1 agonist developed by Eli Lilly, received FDA approval in 2022 and UK MHRA authorisation in 2023. The SURMOUNT-1 trial documented ~22% mean body weight reduction at 72 weeks in the 15 mg arm [PMID:35658024] — approximately 5–7 percentage points more than semaglutide monotherapy. The incremental weight reduction attributable specifically to GIP agonism, over GLP-1 agonism alone, is approximately this 5–7% difference.
The Tirzepatide + Retatrutide + AOD-9604 metabolic stack page documents the research protocol context for the combination of these incretin compounds with the GH-fragment lipolytic peptide.
Glucagon receptor: the third agonist and energy expenditure
Glucagon, secreted by pancreatic α-cells, has classically been framed as the counter-regulatory hormone to insulin: it raises blood glucose through hepatic glycogenolysis and gluconeogenesis. Adding glucagon receptor (GCGR) agonism to an incretin agonist therefore appears paradoxical — why would a compound intended to improve metabolic outcomes stimulate glucose output?
The rationale is energy expenditure. GCGR activation in adipose tissue and liver increases thermogenesis and fatty acid oxidation, raising basal metabolic rate by approximately 15–25% in preclinical models. At the doses used in triple-agonist formulations, the hyperglycaemic effect of GCGR agonism is blunted by the dominant GLP-1R-mediated insulin secretion, leaving the energy-expenditure effect predominant [PMID:37389770].
Retatrutide, the triple GIP/GLP-1/GCGR agonist developed by Eli Lilly, entered Phase II trials with a step-up titration schedule. The published Phase II results reported approximately 24% mean body weight reduction at 48 weeks in the 12 mg arm — the largest pharmacologically induced weight loss in a published human peptide trial at the time of publication [PMID:37389770]. Retatrutide's Phase III programme (TRIUMPH trials) was underway as of 2026; regulatory submission is anticipated in 2026–2027.
The timeline from exenatide to Retatrutide
| Year | Compound | Mechanism | Key Clinical Result |
|---|---|---|---|
| 2005 | Exenatide (Byetta) | GLP-1R agonist | First GLP-1 agonist approval; ~5% weight loss |
| 2010 | Liraglutide (Victoza) | GLP-1R agonist | HbA1c reduction; 3 mg dose for obesity |
| 2021 | Semaglutide (Wegovy) | GLP-1R agonist | STEP-1: ~15% weight loss |
| 2022 | Tirzepatide (Mounjaro) | GIP/GLP-1R dual | SURMOUNT-1: ~22% weight loss |
| 2023 | Retatrutide | GIP/GLP-1/GCGR triple | Phase II: ~24% weight loss at 48 weeks |
Why this matters for the research-peptide conversation
The incretin class is the only peptide class where the full translational chain from receptor biology to Phase III human trial data is publicly available and independently replicated. This makes the GLP-1/GIP/GCGR literature uniquely valuable as a methodological reference point: the receptor biology, pharmacokinetic engineering decisions, clinical trial design, and human outcome data are all published and peer-reviewed.
For most other research peptides — BPC-157, TB-500, Epitalon, Semax — the translational chain stops at rodent in vivo data. The incretin class demonstrates what is required to complete that chain, and the cost (approximately $2–3 billion per approved compound) explains why most research peptides have not undertaken it.
For detailed per-compound pharmacology including receptor binding profiles and published pharmacokinetic data for each incretin compound, PeptideAuthority.co.uk maintains individual monographs on Tirzepatide and Retatrutide with direct citations to the Phase II trial literature.